Intercell teams up with GSK for patch-based vaccines
This article was originally published in Clinica
Executive Summary
Austrian biotech firm Intercell is to collaborate with GlaxoSmithKline (GSK) Biologicals on the development and commercialisation of needle-free, patch-based vaccines. The agreement will see the two firms commercialise Intercell’s vaccine patch for travellers’ diarrhoea (TD), which is currently in phase III trials, and work on future pandemic influenza vaccination patch technology. The companies will combine GSK’s patch technology with Intercell’s candidate vaccines. There are presently no vaccines available for TD, said the company. Financial terms of the deal were not disclosed. According to Vienna-based Intercell, the patch technology could provide a new way of delivering vaccines faster, more easily and with fewer doses. Intercell says that each year, around 20 million travellers develop TD while visiting endemic areas such as Asia, Africa and South America.
You may also be interested in...
Alere aided by professional diagnostics sales in fourth quarter
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra and Stout to work on expandable interbody device
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe eyes portfolio expansion to help boost molecular diagnostics credentials
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals